Outsourcing - Articles and news items

CPhI logo

Groundbreaking program lineup announced for CPhI North America’s Connect Conference

Supplier news / 21 March 2017 / CPhI

Hear from 55+ pharma industry leaders including, Merck, Eli Lilly, Pfizer, BASF, and Catalent, over three days of educational sessions…

CPhI report highlights potential risks in biologics supply chain outsourcing

Industry news / 15 October 2015 / Victoria White

CPhI highlights these risks in the fourth and final section of its 2015 annual report, The Outsourcing perspective…

Outsourcing in the analytical and microbiology area

Outsourcing in the analytical and microbiology area

Contract Research, Issue 2 2015 / 20 April 2015 / Roger A. Stroud, R Stroud Pharmaceutical Quality Solutions Limited

Increasing numbers of pharmaceutical companies are considering outsourcing in the area of analytical and microbiological testing, from the very smallest start-up, virtual, or small company up to the largest multinational. This article will examine the factors that lead to a company deciding to outsource, and provides invaluable guidance on the important considerations that should be made before, during and after the outsourcing process in order to ensure it runs as smoothly as possible…

Allen Burgenson, Lonza Walkersville

Is Big Pharma still actively engaging in outsourcing?

Supplier news / 19 February 2014 / Allen L. Burgenson, Manager - Regulatory Affairs, Lonza Walkersville, Inc

Allen L. Burgenson, Manager – Regulatory Affairs, Lonza Walkersville, Inc answers the question “From a vendor perspective, do you conclude that Big Pharma is still actively engaging in outsourcing of the activities that you have expertise in?”

0813 TSP China PR

Evolving landscape of pharmaceutical outsourcing in China

Contract Research, Issue 5 2012 / 22 October 2012 / Xiaorong He, Senior Research Fellow, Boehringer-Ingelheim

China’s economic growth has shocked and awed the world, with its GDP growing at an average rate of 10 per cent for 30 years. The astonishing economic growth has also spurred rapid growth of pharmaceutical outsourcing business in China. In the past, China had been the major source of raw materials, basic intermediates and commodity bulk drugs for the pharmaceutical industry. Starting five to 10 years ago, China gradually moved up the value chain, providing a wide spectrum of services encompassing drug discovery support, preclinical development, clinical trial and contract manufacturing services to western Pharmaceutical and biotech companies…

Discovery chemistry outsourcing

Contract Research, Issue 2 2012 / 26 April 2012 / Luigi La Vecchia, Director of the Preparations Laboratories, Novartis Institute for Biomedical Research

In 2002, Novartis decided to create a new research centre in Cambridge, MA. This was accompanied by a significant increase in headcount in medicinal chemistry. Within two years, this resulted in a strongly increased demand for prep-scale synthesis which in turn led to priority issues and to prolonged turnaround times due to lack of resources in our Preparations Laboratories. In order to debottleneck time critical scale-up activities, the Preparations Laboratories was asked in 2004 to introduce outsourcing as an alternative option to an in-house increase of headcount…

Outsourcing in early drug discovery: Evolution and opportunities

Contract Research, Issue 2 2012 / 26 April 2012 / Jayshree Mistry, Paul Lloyd, Kevin Oliver and Peter North, GlaxoSmithKline R&D and Duncan Judd, Awridian

This article describes the evolution of outsourcing within early drug discovery at GlaxoSmithKline (GSK), specifically for chemistry services applied to developing a compound from the screening hit through lead optimisation. It will touch on different business models, factors to consider when selecting potential CROs, the benefits of outsourcing and CRO management…

Specialisation impacts the European Contract Research Services market

Industry Focus 2007, Past issues / 7 April 2008 /

Research within the pharmaceutical industry has tripled in the past 25 years, with the pipelines of the top companies doubling. Stricter regulations, guidelines, price and reimbursement legislation all result in a changing business environment. The growing market in drug development and increase in research and development (R&D) investment, including that of small service companies; coupled with an increase in development costs; the importance of timely development of new products and the aim of reducing time-to-market are all important financial considerations for achieving business growth.

Contract Manufacturing Organisations poised for great opportunities

Industry Focus 2007, Past issues / 7 April 2008 /

In the highly competitive contract manufacturing outsourcing (CMO) market the industry is on the rise with pharmaceutical and biotechnology companies targeting their resources towards marketing, rather than production and drug discovery. Pharmaceutical and biopharmaceutical companies are faced with the need to outsource the manufacture of their products for a variety of reasons.


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...